Selecta Biosciences

General Information

We are a clinical-stage biopharmaceutical company using our proprietary synthetic vaccine particle, or SVP, technology to discover and develop targeted therapies that are designed to modulate the immune system to effectively and safely treat rare and serious diseases. Many such diseases are treated with biologic therapies that are foreign to the patient’s immune system and therefore, elicit an undesired immune response. Of particular concern are anti-drug antibodies, or ADAs, which are produced by the immune system in response to biologic therapy and can adversely affect the efficacy and safety of treatment. Our proprietary SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of ADAs in response to life-sustaining biologic drugs.

Employees: 54
Founded: 2007
Contact Information
Address 480 Arsenal Street, Building One, Watertown, MA 02472, US
Phone Number (617) 923-1400
Web Address
View Prospectus: Selecta Biosciences
Financial Information
Market Cap $250.6mil
Revenues $7.1 mil (last 12 months)
Net Income $-35.0 mil (last 12 months)
IPO Profile
Symbol SELB
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $14.00
Est. $ Volume $70.0 mil
Manager / Joint Managers UBS Investment Bank/ Stifel
CO-Managers Canaccord Genuity/ Needham & Company
Expected To Trade: 6/22/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change